RKLB · Rocket Lab Corporation — research history

Score falls well below the 45-point threshold due to zero insider buying, material insider selling, negative profitability, and active dilution risks. Despite bullish options flow and near-term catalysts (Nasdaq inclusion, earnings), the stock is priced for perfection after a 300% run, leaving no margin of safety or asymmetric risk/reward for publication.

Score falls well below the 45-point threshold due to zero insider buying, material insider selling, negative profitability, and active dilution risks. Despite bullish options flow and near-term catalysts (Nasdaq inclusion, earnings), the stock is priced for perfection after a 300% run, leaving no margin of safety or asymmetric risk/reward for publication.

Rocket Lab is a fundamentally strong space-access company with 75 Electron launches delivered and Neutron in development, yet it has run +300% from its lows and now sits near its 52-week high at ~$102. The stock just suffered an acute -10.8% single-session selloff following the SpaceX IPO (sell-the-news on competing space names). The options flow shows genuine OTM call whale blocks (9 blocks, net $3.85M bullish bias), but insider filings reveal mostly RSU grants and trust reshuffles rather than open-market CEO/CFO purchases — only one director sale from Alexander Slusky ($4.94M at ~$123.60) in the cluster window. With forward P/E deeply negative (pre-profitability), the stock is priced for perfection after its parabolic move; Q2 earnings on Aug 6 and Nasdaq-100 index inclusion (effective June 22) are near-term catalysts, but neither guarantees upward re-rating from current levels.

The investigation triggered on a cluster of 5 Form 4 filings in ~14 days (05/22-05/28). However, after reading each filing, ALL transactions were either: (a) sell-to-cover for tax withholding on RSU vesting (CFO Spice, COO Klein, GC Kampani, Pres. Clevenger — all S code sells), or (b) routine RSU grants to directors under the compensation policy (Slusky, Saintil, Possenriede — A code). CEO Beck's filing showed conversion of preferred shares held via his Equatorial Trust (C code, not a new cash purchase). There were zero open-market P-code purchases from insiders. RKLB has run +145% YTD to ~$122, at the 52-week high as of last week before today's sharp -15% selloff on space-sector rotation and Blue Origin/New Glenn news. The stock is deeply unprofitable (forward P/E: N/A; EBITDA-negative), trading at 120x EV/Revenue ($115B market cap / $680M TTM revenue). Neutron's targeted Q4 2026 debut is the primary forward catalyst, alongside SpaceX IPO-driven space-sector re-rating enthusiasm. Options flow shows bearish put-skew (P/C ratio: 1.67) with whale-sized OI at strikes 100-126. No asymmetric long setup; stock appears fully valued.

Rocket Lab is a pre-profitability space company ($200M+ revenue run rate growing 63% YoY) that has staged a dramatic +157% YTD rally to all-time highs near $139, driven by SpaceX IPO anticipation and sector momentum. The investigation found two material bearish signals: (1) the May 20 equity distribution agreement authorizing up to $3B in ATM share dilution — an extraordinary amount relative to RKLB's existing market cap of ~$79B that has already begun spooking investors; and (2) a company still deeply loss-making with no clear near-term path to profitability, making traditional valuation metrics irrelevant. Insiders have been net sellers across the trailing 6 months despite elevated prices, options flow is mixed, and the stock's RSI of 69.3 on an extended base presents poor timing risk for any directional bet.

Score sits at 28 due to zero smart-money accumulation, unprofitable status at all-time highs, and active anti-signal gates (dilution and >30% customer concentration). The stock has already run +188% YTD with elevated RSI, pricing in near-term catalysts; no margin of safety exists for a long thesis, and the current price/IV environment does not support a viable covered call or strangle without taking asymmetric downside risk.

Rocket Lab is a high-quality end-to-end space company with proven launch reliability (77 successful missions) and a rapidly growing space systems segment built via acquisitions. Revenue grew 63% YoY to $679M FY2025, but the stock has run +188% YTD to all-time highs near $138 — now sitting at ~$133 with RSI at 71.9. The company is still deeply loss-making (operating margin -22%), and traditional P/E ratios are meaningless on an unprofitable pre-revenue-scale name. Recent M&A activity (Mynaric AG, Motiv Space Systems) expands its defense infrastructure story, but the valuation appears to price in near-perfect execution of Neutron development and space systems synergy capture with minimal discount for risk. No open-market insider purchases from executives were found; director selling was observed at higher prices. The upcoming earnings catalyst on Aug 6 is real (record backlog cited: $2.22B) but already well-known to the market.

Score falls well below the 50-point threshold due to extreme valuation (1938x forward P/E), zero insider buying, and a $1B ATM shelf creating persistent dilution overhang. The recent 26% surge to all-time highs leaves no asymmetric entry, and while IV is elevated, the structural overhang and lack of margin of safety make any income or long structure too risky relative to the edge.

Rocket Lab delivered a massive Q1 2026 beat (record $200.3M revenue, +63.5% YoY; EPS -$0.07 in line) alongside four simultaneous catalysts on May 7: its largest-ever launch contract ($2.2B+ backlog), acquisition of Motiv Space Systems for space robotics, Anduril HASTE hypersonic deal, and Raytheon/Space Force intercept program selection. The stock surged ~26% the day after reporting and hit an all-time high near $100. However, RKLB trades at a 1938x forward P/E with no profits, carries -$270M annualized FCF burn, completed a $1B ATM shelf registration in March (potential dilution), and insider activity over the past six months is exclusively pre-scheduled sell-to-cover or 10b5-1 plan sales — zero open-market purchases from any executive. The technical setup shows a late-cycle breakout with RSI at 65.9 and IV elevated at 80–90% across near-term expirations, creating an attractive income premium but no asymmetric long-side entry given the stretched valuation.